On June 30, 2022, Faeth Therapeutics, a cancer metabolism company, announced the completion of a Series A financing of $47 million led by S2G Ventures. Khosla Ventures and Future Ventures also participated in the Series A, along with additional support from Digitalis, KdT Ventures, AgFunder, and Cantos. The company has raised a total of $67 million to date. Wilson Sonsini Goodrich & Rosati represented Faeth Therapeutics in the transaction.

The proceeds of the financing will be used to advance Faeth's clinical trials that combine nutrient control, therapeutics, and digital tools to inhibit cancer metabolism.

The Wilson Sonsini team that represented Faeth Therapeutics in this transaction includes: Jennifer Fang and Andrew Thompson with special assistance from Vern Norviel, Tony Jeffries, Charlotte Kim, Mark Solakian, and Tait Graves.

For more information, please see Faeth Therapeutics’ news release. Further coverage can be found on Business Insider and San Francisco Business Times.